1-99915440-GAA-GAAA
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000642.3(AGL):c.4221dupA(p.Leu1408IlefsTer14) variant causes a frameshift change. The variant allele was found at a frequency of 0.00000744 in 1,612,970 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. L1408L) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000642.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AGL | NM_000642.3 | c.4221dupA | p.Leu1408IlefsTer14 | frameshift_variant | Exon 31 of 34 | ENST00000361915.8 | NP_000633.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151374Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461478Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727068
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151492Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 73986
ClinVar
Submissions by phenotype
Glycogen storage disease type III Pathogenic:8
Variant summary: AGL c.4221dupA (p.Leu1408IlefsX14) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 251128 control chromosomes. c.4221dupA has been reported in the literature in at-least one individual affected with Glycogen Storage Disease Type III and subsequently cited by others (example, Pavari_1998, Fukuda_2000). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in absence of normal leukocyte debrancher enzyme activity in a sample obtained from a patient who was compound heterozygous for this variant and another frameshifting mutation in the AGL gene (Pavari_1998). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic with one citing overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as pathogenic. -
- -
- -
- -
- -
This sequence change creates a premature translational stop signal (p.Leu1408Ilefs*14) in the AGL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGL are known to be pathogenic (PMID: 19299494). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with glycogen storage disease (PMID: 9584265). ClinVar contains an entry for this variant (Variation ID: 189052). For these reasons, this variant has been classified as Pathogenic. -
- -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at